ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Mallinckrodt partners with Silence Therapeutics for RNAi drugs
July 22, 2019Mallinckrodt has partnered with Silence Therapeutics for the development and commercialisation of RNA interference (RNAi) drugs to treat patients with complement-mediated diseases. -
The Big Era for Investment of “RNAi Drugs” from the Perspective of Two Newly Approved Drugs by FDA
June 16, 2017FDA approved the Exondys 51 (eteplirsen) of Sarepta Therapeutics on September 19, 2016 for treating exon 51 skipping Duchenne muscular dystrophy (DMD).
Pharma Sources Insight January 2025
